Kurs & Likviditet
Prenumeration
Kalender
2024-11-06 | Kvartalsrapport 2024-Q3 |
2024-08-26 | Kvartalsrapport 2024-Q2 |
2024-05-17 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2024-05-16 | Årsstämma 2024 |
2024-05-07 | Kvartalsrapport 2024-Q1 |
2024-02-15 | Bokslutskommuniké 2023 |
2023-11-28 | Extra Bolagsstämma 2023 |
2023-10-26 | Kvartalsrapport 2023-Q3 |
2023-08-24 | Kvartalsrapport 2023-Q2 |
2023-05-17 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2023-05-16 | Årsstämma 2023 |
2023-04-28 | Kvartalsrapport 2023-Q1 |
2023-02-20 | Bokslutskommuniké 2022 |
2023-02-16 | Extra Bolagsstämma 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-07-15 | Kvartalsrapport 2022-Q2 |
2022-05-19 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2022-05-18 | Årsstämma 2022 |
2022-05-05 | Kvartalsrapport 2022-Q1 |
2022-02-17 | Bokslutskommuniké 2021 |
2021-11-12 | Kvartalsrapport 2021-Q3 |
2021-08-27 | Kvartalsrapport 2021-Q2 |
2021-05-12 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2021-05-11 | Årsstämma 2021 |
2021-05-06 | Kvartalsrapport 2021-Q1 |
2021-03-05 | Extra Bolagsstämma 2021 |
2021-02-26 | Bokslutskommuniké 2020 |
2020-11-06 | Kvartalsrapport 2020-Q3 |
2020-08-21 | Kvartalsrapport 2020-Q2 |
2020-07-02 | Extra Bolagsstämma 2020 |
2020-05-15 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2020-05-14 | Årsstämma 2020 |
2020-05-08 | Kvartalsrapport 2020-Q1 |
2020-02-14 | Bokslutskommuniké 2019 |
2019-11-08 | Kvartalsrapport 2019-Q3 |
2019-08-22 | Kvartalsrapport 2019-Q2 |
2019-08-21 | Extra Bolagsstämma 2019 |
2019-05-09 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2019-05-08 | Kvartalsrapport 2019-Q1 |
2019-05-08 | Årsstämma 2019 |
2019-02-15 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-22 | Kvartalsrapport 2018-Q2 |
2018-05-09 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2018-05-08 | Kvartalsrapport 2018-Q1 |
2018-05-08 | Årsstämma 2018 |
2018-03-05 | Extra Bolagsstämma 2018 |
2018-02-16 | Bokslutskommuniké 2017 |
2017-11-28 | Kvartalsrapport 2017-Q3 |
2017-09-15 | Extra Bolagsstämma 2017 |
2017-08-31 | Kvartalsrapport 2017-Q2 |
2017-05-23 | Kvartalsrapport 2017-Q1 |
2017-05-23 | Årsstämma 2017 |
2017-02-16 | Bokslutskommuniké 2016 |
2016-11-22 | Kvartalsrapport 2016-Q3 |
2016-08-31 | Kvartalsrapport 2016-Q2 |
2016-05-17 | Extra Bolagsstämma 2016 |
2016-04-28 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2016-04-27 | Kvartalsrapport 2016-Q1 |
2016-04-27 | Årsstämma 2016 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-11-24 | Kvartalsrapport 2015-Q3 |
2015-08-26 | Kvartalsrapport 2015-Q2 |
2015-05-20 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2015-05-19 | Årsstämma 2015 |
2015-05-19 | Kvartalsrapport 2015-Q1 |
2015-02-25 | Bokslutskommuniké 2014 |
2014-11-27 | Kvartalsrapport 2014-Q3 |
2014-11-21 | Extra Bolagsstämma 2014 |
2014-08-21 | Kvartalsrapport 2014-Q2 |
2014-05-15 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2014-05-14 | Kvartalsrapport 2014-Q1 |
2014-05-14 | Årsstämma 2014 |
2014-02-24 | Bokslutskommuniké 2013 |
2013-11-27 | Kvartalsrapport 2013-Q3 |
2013-08-20 | Kvartalsrapport 2013-Q2 |
2013-05-16 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2013-05-15 | Kvartalsrapport 2013-Q1 |
2013-05-15 | Årsstämma 2013 |
2013-02-28 | Bokslutskommuniké 2012 |
2013-01-08 | Extra Bolagsstämma 2013 |
2012-11-21 | Kvartalsrapport 2012-Q3 |
2012-08-21 | Kvartalsrapport 2012-Q2 |
2012-05-24 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2012-05-23 | Årsstämma 2012 |
2012-05-23 | Kvartalsrapport 2012-Q1 |
2012-02-22 | Bokslutskommuniké 2011 |
2011-11-23 | Kvartalsrapport 2011-Q3 |
2011-08-23 | Kvartalsrapport 2011-Q2 |
2011-05-27 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2011-05-26 | Kvartalsrapport 2011-Q1 |
2011-05-26 | Årsstämma 2011 |
2011-02-16 | Bokslutskommuniké 2010 |
2010-11-24 | Kvartalsrapport 2010-Q3 |
2010-05-28 | X-dag ordinarie utdelning SEZI 0.00 SEK |
2010-05-27 | Kvartalsrapport 2010-Q1 |
2009-11-25 | Kvartalsrapport 2009-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
The extraordinary general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 19 October 2023, whereby the shareholders primarily resolved on the following matter.
Resolution on the approval of the board of directors’ resolution on a directed share issue
In accordance with previously published information, the board of directors resolved 25 September 2023 on a directed issue of shares, subject to the subsequent approval of the extraordinary general meeting. The general meeting resolved today to approve the board of directors’ resolution on a directed issue of a maximum of 18,000,000 shares. The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong to Nordic Issuing AB, for re-transfer to a limited number of investors pursuant to existing agreements.
The Company’s share capital will increase by a maximum of SEK 2,250,000 through a directed issue of a maximum of 18,000,000 shares. The subscription prices for the shares in the new issue is SEK 0.125 per share, corresponding to the quota value for the Company’s share. However, the price to be used at re-transfer to investor shall correspond to SEK 6.50 per share. Subscription with subscription rights shall be made by cash payment not later than 20 October 2023.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.